[1]国家肿瘤微创治疗产业技术创新战略联盟护理专业委员会,中国抗癌协会肿瘤介入学专业委员会.肝动脉灌注化疗持续动脉给药及管路护理专家共识[J].介入放射学杂志,2023,32(06):519-526.
 Nursing Professional Committee of Strategic Alliance of Technology Innovation for Minimally Invasive Tumor Therapy,Professional Committee on Cancer Intervention of China Anti-Cancer Association.Expert consensus on nursing standard of continuous arterial infusion and catheter management for patients receiving hepatic artery infusion chemotherapy[J].journal interventional radiology,2023,32(06):519-526.
点击复制

肝动脉灌注化疗持续动脉给药及管路护理专家共识()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年06
页码:
519-526
栏目:
指南与共识
出版日期:
2023-06-28

文章信息/Info

Title:
Expert consensus on nursing standard of continuous arterial infusion and catheter management for patients receiving hepatic artery infusion chemotherapy
作者:
国家肿瘤微创治疗产业技术创新战略联盟护理专业委员会 中国抗癌协会肿瘤介入学专业委员会
Author(s):
Nursing Professional Committee of Strategic Alliance of Technology Innovation for Minimally Invasive Tumor Therapy Professional Committee on Cancer Intervention of China Anti-Cancer Association
关键词:
【关键词】 肝癌 肝动脉灌注化疗 持续动脉给药 管路 护理 并发症 专家共识
文献标志码:
A
摘要:
【摘要】 为促进肝动脉灌注化疗(HAIC)患者持续动脉给药、管路护理规范化和标准化,保证患者安全,改善预后,本共识通过系统总结研究证据和专家意见,结合护理临床实践,从HAIC适应证、禁忌证、动脉给药方法、动脉导管固定方法、患者监测和指导、持续动脉给药输注设备使用规范、肝动脉留管相关并发症及护理等方面进行全面论述,旨在为HAIC持续动脉给药及管路护理工作提供指引。

参考文献/References:

[1] 刘晓侃,张超杰,赵 辉. 肝动脉灌注化疗及其联合治疗在中晚期肝细胞癌中的应用进展[J]. 肝脏, 2021, 26:1411- 1414.
[2] 刘少兴,朱 旭.肝动脉灌注化学治疗中晚期肝癌进展[J]. 中国介入影像与治疗学, 2020, 17:632- 635.
[3] Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy[J]. Liver Cancer, 2015, 4: 188- 199.
[4] He MK,Le Y,Li QJ,et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non- randomized study[J]. Chin J Cancer, 2017, 36: 83.
[5] 王春青,胡 雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30:964- 967.
[6] 中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20:754- 759.
[7] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41:618- 632.
[8] Surveillance group,Diagnosis group,Staging group,et al. Mana-gement consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gast-roenterological Society of Taiwan[J]. J Formos Med Assoc, 2018, 117: 381- 403.
[9] 郭建海,朱 旭. 晚期原发性肝癌的肝动脉灌注化疗[J]. 肝癌电子杂志, 2019, 6:20- 23.
[10] 中国抗癌协会肿瘤介入学专业委员会. 中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会.改良式经皮肝动脉化疗药盒植入技术中国专家共识(2022版)[J]. 介入放射学杂志, 2022, 31:633- 641.
[11] Liang HL,Huang JS,Lin YH,et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route[J]. Acta Radiol, 2007, 48: 734- 740.
[12] 郭秀军,郭秀娟,李歧梅,等. 5例经桡动脉穿刺肝癌化疗栓塞介入治疗患者的护理[J]. 中华护理杂志, 2006, 41:1032.
[13] 许书榕. 肝动脉灌注化疗(HAIC)治疗肝细胞癌(HCC)的研究进展[J]. 复旦学报(医学版), 2019, 46:814- 818, 823.
[14] Yamashita T. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy[J]. Clin Drug Investig, 2012, 32: 15- 23.
[15] Zheng K,Zhu X,Fu S,et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial[J]. Rad- iology, 2022, 303: 455- 464.
[16] Wang X,Hu J,Cao G,et al. Phase Ⅱ study of hepatic arterial infusion chemotherapy with oxaliplatin and 5- fluorouracil for advanced perihilar cholangiocarcinoma[J]. Radiology, 2017, 283: 580- 589.
[17] 程永德,程英升,颜志平. 常见恶性肿瘤介入治疗指南[M]. 北京:科学出版社, 2013.
[18]卢利云. 6例肝动脉灌注化疗治疗晚期原发性肝癌的护理体会[J]. 加速康复外科杂志, 2020, 3:123- 126.
[19] 梁红玲.微量泵持续肝动脉灌注栓塞治疗原发性肝癌的护理[J]. 南京军医学院学报, 2003, 25:118- 119.
[20] Barber FD,Fabugais- Nazario LE. What’s old is new again: patients receiving hepatic arterial infusion chemotherapy[J]. Clin J Oncol Nurs, 2003, 7: 647- 652.
[21] 王奕敏,周志欢,何凤英,等. 卧床体位管理联合踝泵运动在原发性肝癌患者TAI术后护理中的应用[J]. 齐鲁护理杂志, 2021, 27:14- 16.
[22] 黄 萍,黄丽云. 经动脉药盒持续性肝动脉灌注化疗的护理[J]. 包头医学院学报, 2011, 27:89- 90.
[23] 万玉莉. 转移性肝癌经药盒植入系统进行肝动脉灌注化疗的辨证施护[J]. 护理研究, 2010, 24:2577- 2578.
[24] Chevallier O, Mvouama S, Pellegrinelli J, et al. Percutaneous implantation of a microcatheter- port system for hepatic arterial infusion chemotherapy of unresectable liver tumors: technical feasibility,functionality,and complications[J]. Diagnostics (Basel), 2021, 11: 399.
[25] 李含英,尤国美,潘 琴,等. 经桡动脉置管行持续灌注化疗治疗肝癌的安全性和舒适性研究[J]. 浙江医学, 2020, 42:2366- 2367, 2373.
[26] Zhao X,Sun X,Jing J,et al. Safety study of FOLFOX- HAIC in relieving bed restriction[J]. J Interv Med, 2021, 4: 203- 207.
[27] 翟东红.原发性肝癌肝动脉置管百特泵持续灌注化疗的临床护理[J]. 肿瘤预防与治疗, 2010, 23:244- 245.
[28] 何 健. FOLFOX方案肝动脉灌注化疗治疗晚期肝癌的预后模型研究[D]. 汕头:汕头大学, 2021.
[29] 肖书萍,肖 芳,陈冬萍,等. 肝细胞癌经动脉化疗栓塞治疗围术期护理策略专家共识[J]. 临床放射学杂志, 2022, 41:212- 216.
[30] Arai Y,Takeuchi Y,Inaba Y,et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy[J]. Tech Vasc Interv Radiol, 2007, 10: 30- 37.
[31] 王广玲,曹继艳,孙秀英. 肝癌插管化疗中微电脑输液泵的应用[J]. 齐鲁护理杂志, 1998,4:28.
[32] Barnett KT,Malafa MP. Complications of hepatic artery infusion: a review of 4580 reported cases[J]. Int J Gastrointest Cancer, 2001, 30: 147- 160.
[33] Imamine R,Shibata T,Shinozuka K,et al. Complications in hepatic arterial infusion chemotherapy: retrospective comparison of catheter tip placement in the right/left hepatic artery vs. the gastroduodenal artery[J]. Surg Today, 2017, 47: 851- 858.
[34] Kuroiwa T,Honda H,Yoshimitsu K,et al. Complications encoun-tered with a transfemorally placed port- catheter system for hepatic artery chemotherapy infusion[J]. Cardiovasc Intervent Radiol, 2001, 24: 90- 93.
[35] Seki H,Kimura M,Yoshimura N,et al. Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery[J]. Clin Radiol, 1999, 54: 221- 227.
[36] 陈敏山,胡自力. 肝动脉灌注化疗在肝癌转化治疗中的研究进展[J]. 中华消化外科杂志, 2021, 20:171- 177.
[37] Habbe TG,McCowan TC,Goertzen TC,et al. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy[J]. J Vasc Interv Radiol, 1998, 9: 233- 239.
[38] 周留平. 晚期肝癌肝动脉灌注化疗的观察与护理[J]. 河北中西医结合杂志, 1999, 8:859.
[39] Matsumoto T,Yamagami T,Yoshimatsu R,et al. Hepatic arterial infusion chemotherapy by the fixed- catheter- tip method: retro-spective comparison of percutaneous left subclavian and femoral port- catheter system implantation[J]. AJR Am J Roentgenol, 2014, 202: 211- 215.
[40] Koganemaru M,Abe T,Iwamoto R,et al. Hepatic arterial infusion chemotherapy with a coaxial reservoir system using a non- braided spiral tip microcatheter[J]. Jpn J Radiol, 2012, 30: 10- 17.
[41] Andrews JC,Griggs TJ,Ensminger WD,et al. Local thrombolytic therapy for hepatic artery thrombosis following chemotherapy infusion catheter placement[J]. Invest Radiol, 1987, 22: 467- 471.
[42] 徐 波,耿翠芝. 肿瘤治疗血管通道安全指南[M]. 北京:中国协和医科大学出版社, 2015.
[43] Kiekkas P,Aretha D,Panteli E,et al. Unplanned extubation in critically ill adults: clinical review[J]. Nurs Crit Care, 2013, 18: 123- 134.
[44] 张 燕,吴桂丽,范冠华. 基于关联规则的住院患者非计划性拔管危险因素分析[J]. 护理学杂志, 2021, 36:44- 46.
[45] 朱胜春,金钰梅. 住院患者意外拔(脱)管临床特征分析及对策[J]. 中华护理杂志, 2009, 44:256- 258.
[46] 庄 燕,俞家顺,李晓静. 经桡动脉冠状动脉介入术后早期握力锻炼对预防桡动脉闭塞的研究[J]. 山西医药杂志, 2022, 51:487- 491.
[47] 张 羿,陈 芬,皮文婕,等. 简化手指操对冠状动脉造影术后桡动脉闭塞及相关并发症的预防作用[J]. 蚌埠医学院学报, 2022, 47:278- 280.
[48] 钟继明,李 浪,陆永光,等. 经桡动脉冠心病介入诊疗中桡动脉痉挛的发生及其预测因素[J]. 介入放射学杂志, 2011, 20:265- 268.
[49] 刘旭艳,房凤岭. 经桡动脉行冠状动脉介入治疗后并发症的研究进展[J]. 齐齐哈尔医学院学报, 2021, 42:513- 517.
[50] 经远端桡动脉行冠状动脉介入诊疗中国专家共识专家组. 经远端桡动脉行冠状动脉介入诊疗中国专家共识[J]. 中国介入心脏病学杂志, 2020, 28: 667- 674.
[51] 石兰萍,唐 蓉,魏莹莹,等. 术前皮肤准备方案的构建及应用[J]. 中华护理杂志, 2020, 55:723- 726.
[52] 赵 辉,刘远庭,张松林,等. 皮下泵化疗对原发性晚期肝癌的治疗价值[J]. 现代实用医学, 2005, 17:278- 279.

相似文献/References:

[1]肖丽霞,吴熙中,夏伟,等.经皮穿刺药盒植入术护理体会[J].介入放射学杂志,1998,(02):122.
[2]邢丽华.原发性肝癌的介入治疗次数及单纯栓塞的意义[J].介入放射学杂志,1998,(03):166.
[3]韩旭,杨家政,左庆云,等.选择性肝动脉灌注化疗及栓塞治疗原发性巨块型肝癌[J].介入放射学杂志,1998,(03):171.
[4]杨熙章,吴纪瑞,杨永岩,等.灌注化疗预防肝癌术后复发[J].介入放射学杂志,1999,(02):32.
[5]陆莎莎,程永德.动脉灌注化疗与栓塞治疗肝癌后声像图变化的探讨[J].介入放射学杂志,1992,(01):43.
[6]吴驰,王建华,颜志平,等.脾动脉栓塞治疗肝癌合并脾亢的应用观察[J].介入放射学杂志,1994,(01):48.
[7]倪鎏达,陈成伟,茹素娟,等.中晚期肝癌化学免疫治疗与单纯TAE治疗疗效比较[J].介入放射学杂志,1994,(02):82.
[8]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
 .The volume of Lipiodol used in TACE: its current situation and research progress [J].journal interventional radiology,2012,(06):348.
[9]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗30例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
 ,,et al.TACE combined with radiofrequency ablation for massive primary hepatocellular carcinomas: a clinical therapeutic evaluation [J].journal interventional radiology,2012,(06):322.
[10]张   磊,陆骊工,李   勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
 ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(06):968.

备注/Memo

备注/Memo:
(收稿日期:2022- 10- 21)
(本文编辑:谷 珂)
更新日期/Last Update: 2023-06-26